{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:12Z","timestamp":1792553412678,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201610GSD-385560-272687"],"award-info":[{"award-number":["201610GSD-385560-272687"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015904","name":"Alexander Mosley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jad.2023.04.105","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:53:04Z","timestamp":1683121984000},"page":"100-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change"],"prefix":"10.1016","volume":"334","author":[{"given":"Richard J.","family":"Zeifman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice M.","family":"Monson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0010","article-title":"Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: an interpretive phenomenological analysis","author":"Agin-Liebes","year":"2021","journal-title":"J. Humanist. Psychol."},{"issue":"3","key":"10.1016\/j.jad.2023.04.105_bb0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/02698811221080165","article-title":"Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca","volume":"36","author":"Agin-Liebes","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0020","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR","year":"2000"},{"key":"10.1016\/j.jad.2023.04.105_bb0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpsychires.2021.03.062","article-title":"Association between obsessive-compulsive and related disorders and experiential avoidance: a systematic review and meta-analysis","volume":"138","author":"Angelakis","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13543784.2022.2035358","article-title":"Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine","volume":"31","author":"Averill","year":"2022","journal-title":"Expert Opin. Investigatig. Drugs"},{"issue":"11","key":"10.1016\/j.jad.2023.04.105_bb0035","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0022167817706884","article-title":"Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis","volume":"57","author":"Belser","year":"2017","journal-title":"J. Humanist. Psychol."},{"issue":"10","key":"10.1016\/j.jad.2023.04.105_bb0045","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0050","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.beth.2011.03.007","article-title":"Preliminary psychometric properties of the acceptance and action Questionnaire\u2013II: a revised measure of psychological inflexibility and experiential avoidance","volume":"42","author":"Bond","year":"2011","journal-title":"Behav. Ther."},{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0055","article-title":"What is an emotional disorder? A transdiagnostic mechanistic definition with implications for assessment, treatment, and prevention","volume":"26","author":"Bullis","year":"2019","journal-title":"Clin. Psychol."},{"issue":"3","key":"10.1016\/j.jad.2023.04.105_bb0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.jad.2023.04.105_bb0065","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.jad.2023.04.105_bb0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"15","key":"10.1016\/j.jad.2023.04.105_bb0080","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"NEJM"},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/02698811211008567","article-title":"Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?","volume":"36","author":"Carhart-Harris","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109398","article-title":"Canalization and plasticity in psychopathology","author":"Carhart-Harris","year":"2023","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.jad.2023.04.105_bb0095","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.euroneuro.2006.04.008","article-title":"The Montgomery \u00c4sberg and the Hamilton ratings of depression: a comparison of measures","volume":"16","author":"Carmody","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1176\/appi.focus.16407","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"16","author":"Cipriani","year":"2018","journal-title":"Focus"},{"key":"10.1016\/j.jad.2023.04.105_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcbs.2020.01.005","article-title":"Psychedelics and psychological flexibility-results of a prospective web-survey using the acceptance in action questionnaire II","volume":"16","author":"Close","year":"2020","journal-title":"J. Contextual Behav. Sci."},{"key":"10.1016\/j.jad.2023.04.105_bb0110","article-title":"Experiences of psilocybin treatment for clinical conditions: a qualitative meta-synthesis","author":"Crowe","year":"2023","journal-title":"Int. J. Ment. Health Nurs."},{"issue":"7","key":"10.1016\/j.jad.2023.04.105_bb0115","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","author":"Davis","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0120","doi-asserted-by":"crossref","DOI":"10.1177\/2470547020939564","article-title":"Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans","volume":"4","author":"Davis","year":"2020","journal-title":"Chronic Stress"},{"key":"10.1016\/j.jad.2023.04.105_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","article-title":"Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety","volume":"15","author":"Davis","year":"2020","journal-title":"J. Contextual Behav. Sci."},{"issue":"5","key":"10.1016\/j.jad.2023.04.105_bb0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0269881120967878","article-title":"Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD","volume":"35","author":"Davis","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0140","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder","volume":"11","author":"Doss","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2023.04.105_bb0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/13811118.2015.1093983","article-title":"Change in experiential avoidance is associated with reduced suicidal ideation over the course of psychiatric hospitalization","volume":"20","author":"Ellis","year":"2016","journal-title":"Arch. Suicide Res."},{"key":"10.1016\/j.jad.2023.04.105_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.janxdis.2016.06.006","article-title":"Changes in threat-related cognitions and experiential avoidance in group-based transdiagnostic CBT for anxiety disorders","volume":"46","author":"Espejo","year":"2017","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.jad.2023.04.105_bb0155","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10608-019-10063-6","article-title":"Experiential avoidance as a mechanism of change across cognitive-behavioral therapy in a sample of participants with heterogeneous anxiety disorders","volume":"44","author":"Eustis","year":"2020","journal-title":"Cognit. Ther. Res."},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1037\/a0034473","article-title":"The brief experiential avoidance questionnaire: development and initial validation","volume":"26","author":"G\u00e1mez","year":"2014","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.jad.2023.04.105_bb9001","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2023.04.105_bb0165","article-title":"Effects of setting on psychedelic experiences, therapies, and outcomes: a rapid scoping review of the literature","volume":"volume 56","author":"Golden","year":"2022"},{"key":"10.1016\/j.jad.2023.04.105_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","article-title":"Emotional blunting with antidepressant treatments: a survey among depressed patients","volume":"221","author":"Goodwin","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"18","key":"10.1016\/j.jad.2023.04.105_bb0175","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"NEJM"},{"issue":"12","key":"10.1016\/j.jad.2023.04.105_bb0180","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF03395492","article-title":"Measuring experiential avoidance: a preliminary test of a working model","volume":"54","author":"Hayes","year":"2004","journal-title":"Psychol. Rec."},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0200","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/capr.12389","article-title":"Exploring virtue ethics in psychodynamic psychotherapy: latent changes in humility, affect regulation, symptoms and well-being","volume":"21","author":"Jankowski","year":"2021","journal-title":"Couns. Psychother. Res."},{"issue":"6","key":"10.1016\/j.jad.2023.04.105_bb0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0210","doi-asserted-by":"crossref","first-page":"16976","DOI":"10.1038\/s41598-022-18645-3","article-title":"Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0215","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1037\/pha0000165","article-title":"Is antidepressant use associated with difficulty identifying feelings? A brief report","volume":"26","author":"Kajanoja","year":"2018","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0225","doi-asserted-by":"crossref","DOI":"10.1556\/2054.2023.00243","article-title":"Association between mystical-type experiences under psychedelics and improvements in well-being or mental health\u2013a comprehensive review of the evidence","author":"Kangaslampi","year":"2023","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.jad.2023.04.105_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.clinpsy.3.022806.091432","article-title":"Mediators and mechanisms of change in psychotherapy research","volume":"3","author":"Kazdin","year":"2007","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.jad.2023.04.105_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.623985","article-title":"Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness","volume":"12","author":"Kettner","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.883869","article-title":"Decreases in state and trait anxiety post-psilocybin: a naturalistic, observational study among retreat attendees","volume":"13","author":"Kiraga","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.04.105_bb0245","series-title":"The Experiencing Scale: A Research and Training Manual. Two Volumes","author":"Klein","year":"1969"},{"key":"10.1016\/j.jad.2023.04.105_bb0250","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fpsyt.2021.661233","article-title":"Does psychedelic therapy have a transdiagnostic action and prophylactic potential?","volume":"12","author":"Ko\u010d\u00e1rov\u00e1","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2023.04.105_bb0255","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1037\/adb0000554","article-title":"Experiential avoidance and negative affect as predictors of daily drinking","volume":"34","author":"Luoma","year":"2020","journal-title":"Psychol. Addict. Behav."},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1207\/s15327906mbr3901_4","article-title":"Confidence limits for the indirect effect: distribution of the product and resampling methods","volume":"39","author":"MacKinnon","year":"2004","journal-title":"Multivar. Behav. Res."},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0265","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","article-title":"Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin","volume":"51","author":"MacLean","year":"2012","journal-title":"J. Sci. Study Relig."},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0270","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0275","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1037\/met0000086","article-title":"Two-condition within-participant statistical mediation analysis: a path-analytic framework","volume":"22","author":"Montoya","year":"2017","journal-title":"Psychol. Methods"},{"issue":"11","key":"10.1016\/j.jad.2023.04.105_bb0280","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.04.105_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.jad.2023.04.105_bb0290","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0295","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)","volume":"269","author":"Nour","year":"2016","journal-title":"Front. Hum. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","article-title":"Psychedelic psychiatry\u2019s brave new world","volume":"181","author":"Nutt","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jad.2023.04.105_bb0305","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fpsyg.2020.00528","article-title":"Psychological flexibility in depression relapse prevention: processes of change and positive mental health in group-based ACT for residual symptoms","volume":"11","author":"\u00d8stergaard","year":"2020","journal-title":"Front. Psychol."},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/02698811211066709","article-title":"Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience","volume":"36","author":"Peill","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0315","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression","volume":"142","author":"Roseman","year":"2018","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.jad.2023.04.105_bb0320","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.jad.2023.04.105_bb0325","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0330","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.jad.2023.04.105_bb0335","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/sltb.12353","article-title":"Contributions of cognitions, psychological flexibility, and therapeutic alliance to suicidal ideation in psychiatric inpatients","volume":"48","author":"Rufino","year":"2018","journal-title":"Suicide Life Threat Behav."},{"issue":"5","key":"10.1016\/j.jad.2023.04.105_bb0340","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2023.04.105_bb0345","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.biopsych.2005.08.022","article-title":"An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report","volume":"59","author":"Rush","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"20","key":"10.1016\/j.jad.2023.04.105_bb0350","first-page":"22","article-title":"The Mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.04.105_bb0355","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cpr.2017.09.002","article-title":"Emotion regulation as a transdiagnostic treatment construct across anxiety, depression, substance, eating and borderline personality disorders: a systematic review","volume":"57","author":"Sloan","year":"2017","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.jad.2023.04.105_bb0360","doi-asserted-by":"crossref","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.04.105_bb0365","series-title":"Manual for the State\u2013Trait Anxiety Inventory (Form Y) (\u201cSelf-Evaluation Questionnaire\u201d)","author":"Spielberger","year":"1983"},{"key":"10.1016\/j.jad.2023.04.105_bb0370","series-title":"State\u2013Trait Anxiety Inventory: A Comprehensive Bibliography","author":"Spielberger","year":"1989"},{"key":"10.1016\/j.jad.2023.04.105_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.735523","article-title":"Study protocol for \u201cPsilocybin as a treatment for anorexia nervosa: a pilot study\u201d","volume":"12","author":"Spriggs","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2023.04.105_bb0380","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0022167817715966","article-title":"Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress","volume":"57","author":"Swift","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.jad.2023.04.105_bb0385","series-title":"On the Fallibility of Placebo Control and How to Address It: A Case Study in Psychedelic Microdosing","author":"Szigeti","year":"2022"},{"issue":"1","key":"10.1016\/j.jad.2023.04.105_bb0390","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1477-7525-5-63","article-title":"The Warwick-Edinburgh mental well-being scale (WEMWBS): development and UK validation","volume":"5","author":"Tennant","year":"2007","journal-title":"Health Qual. Life Outcomes"},{"issue":"3","key":"10.1016\/j.jad.2023.04.105_bb0395","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09687637.2021.1897331","article-title":"Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment","volume":"28","author":"Thrul","year":"2021","journal-title":"Drugs Educ. Prev. Policy"},{"key":"10.1016\/j.jad.2023.04.105_bb0400","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcbs.2018.09.005","article-title":"The acceptance and action questionnaire-II (AAQ-II) as a measure of experiential avoidance: concerns over discriminant validity","volume":"12","author":"Tyndall","year":"2019","journal-title":"J. Contextual Behav. Sci."},{"issue":"4","key":"10.1016\/j.jad.2023.04.105_bb0405","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/sltb.12084","article-title":"The suicidal ideation attributes scale (SIDAS): community-based validation study of a new scale for the measurement of suicidal ideation","volume":"44","author":"Van Spijker","year":"2014","journal-title":"Suicide Life Threat Behav."},{"key":"10.1016\/j.jad.2023.04.105_bb0410","series-title":"Psilocybin for Depression: The ACE Model Manual","author":"Watts","year":"2021"},{"key":"10.1016\/j.jad.2023.04.105_bb0415","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","article-title":"The use of the psychological flexibility model to support psychedelic assisted therapy","volume":"15","author":"Watts","year":"2020","journal-title":"J. Contextual Behav. Sci."},{"issue":"5","key":"10.1016\/j.jad.2023.04.105_bb0420","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.jad.2023.04.105_bb0425","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1007\/s00213-022-06187-5","article-title":"The Watts connectedness scale: a new scale for measuring a sense of connectedness to self, others, and world","volume":"239","author":"Watts","year":"2022","journal-title":"Psychopharmacol"},{"issue":"12","key":"10.1016\/j.jad.2023.04.105_bb9002","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/da.23065","article-title":"Historic psychedelic drug trials and the treatment of anxiety disorders","volume":"37","author":"Weston","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.04.105_bb0430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance","volume":"11","author":"Wolff","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2023.04.105_bb0435","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/02698811211073758","article-title":"The Acceptance\/Avoidance-promoting experiences questionnaire (APEQ): a theory-based approach to psychedelic drugs\u2019 effects on psychological flexibility","volume":"36","author":"Wolff","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2023.04.105_bb0440","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/jclp.22932","article-title":"Self-compassion, meaning in life, and experiential avoidance explain the relationship between meditation and positive mental health outcomes","volume":"76","author":"Yela","year":"2020","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.jad.2023.04.105_bb0445","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fpsyt.2020.00782","article-title":"Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation","volume":"11","author":"Zeifman","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2023.04.105_bb0450","doi-asserted-by":"crossref","first-page":"39235","DOI":"10.4088\/JCP.21r14057","article-title":"Decreases in suicidality following psychedelic therapy: a meta-analysis of individual patient data across clinical trials","volume":"83","author":"Zeifman","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.04.105_bb0455","series-title":"RElaxed Beliefs-Questionnaire (REB-Q) and REB-Q Self-Report (REB-Q-SR): Administration Manual","author":"Zeifman","year":"2022"},{"key":"10.1016\/j.jad.2023.04.105_bb0460","series-title":"From Relaxed Beliefs Under Psychedelics (REBUS) to Revised Beliefs After Psychedelics (REBAS): Preliminary Development of the RElaxed Beliefs Questionnaire (REB-Q)","author":"Zeifman","year":"2022"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723005906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723005906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:00:16Z","timestamp":1759032016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723005906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":94,"alternative-id":["S0165032723005906"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.04.105","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.04.105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}